Alnylam PharmaceuticalsLTS:0HD2 67 Current Ratio is 3.13 as of Mar. 2026, which is 28% below its 10-year median of 4.33. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $519.03 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 56.73% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alnylam Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 3.13.
Alnylam Pharmaceuticals has a current ratio of 3.13. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Alnylam Pharmaceuticals's Current Ratio or its related term are showing as below:
LTS:0HD2'
s Current Ratio Range Over the Past 10 Years
Min: 2.54 Med: 4.33 Max: 14.61
Current: 3.13
During the past 13 years, Alnylam Pharmaceuticals's highest Current Ratio was 14.61. The lowest was 2.54. And the median was 4.33.
LTS:0HD2's Current Ratio is ranked worse than 56.73% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs LTS:0HD2: 3.13
Alnylam Pharmaceuticals (LTS:0HD2) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Alnylam Pharmaceuticals Current Ratio Related Terms
Alnylam Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Current Ratio of 3.13 as of Mar. 2026. This is 28% below median its historical median of 4.33. Over the past decade, Alnylam Pharmaceuticals' Current Ratio has ranged from 2.54 to 14.61. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #801 out of 1412 companies in the Biotechnology industry, placing it in the top 56.7%.
Is Alnylam Pharmaceuticals' Current Ratio too high?
Alnylam Pharmaceuticals' current Current Ratio of 3.13 is 28% below median its 10-year median of 4.33. Over the past 10 years, this metric has ranged from a low of 2.54 to a high of 14.61. The Biotechnology industry median Current Ratio is 3.89. Alnylam Pharmaceuticals' value of 3.13 is 19.5% below this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #801 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Current Ratio compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #801 out of 1412 companies for Current Ratio. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. Alnylam Pharmaceuticals' value of 3.13 is 19.5% below this benchmark. Historically, Alnylam Pharmaceuticals' own Current Ratio has ranged from 2.54 to 14.61 over the past decade. While the company's 10-year median is 4.33 vs. the industry median of 3.89, Alnylam Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Current Ratio of 3.13 is 19.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Current Ratio is 3.13, which is 28% below median its own 10-year median of 4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $519.03, compared to a current price of $294.38 — trading 43.3% below its estimated fair value. The current Current Ratio is 3.13, which is 28% below median its 10-year median of 4.33 and 19.5% below the Biotechnology industry median of 3.89. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Current Ratio is 3.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $294.38 is trading 43.3% below its estimated GF Value™ of $519.03.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Current Ratio: 3.13 (28% below median its 10-year median of 4.33)
GF Value™: $519.03 vs. price of $294.38 (43.3% below fair value)
Industry Position: 19.5% below the Biotechnology median (#801 of 1412)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
